6 October 2015
New Study Reveals Prolonged And Significant Milk Yield
Reduction From IBR
Dairy cows that have been exposed to the virus that causes Infectious Bovine Rhinotracheitis (IBR) have been shown in a new study to produce 2.6l per day less milk throughout the entire lactation, despite showing few or no signs of the disease (i.e. being sub-clinically infected).
The study was carried out by the animal health and welfare consultancy RAFT Solutions and sponsored by MSD Animal Health (known as Merck Animal Health in the US and Canada). It compared the performance of cattle with antibodies to IBR (seropositive) to those without antibodies (seronegative) over a two year period on an average sized, all-year-round calving pedigree Holstein dairy herd in the north of England.
The average reduction in milk yield recorded in infected cows is significant under any circumstances, and particularly so given the absence of any clinical signs of disease in most animals and the prolonged period of impact.
“IBR is known to be an insidious disease that causes often unseen losses, including milk loss, but this new study highlights the scale of potential damage that infected herds can be suffering,” comments Jonathan Statham of Bishopton Veterinary Group and CEO of RAFT Solutions.
“This is a disease that has been shown to be present in up to 70% of herds in some parts of the country, and in many cases it may well be present without herd managers being aware of it.
“Clinical signs include respiratory problems, infertility and abortion, but it may also affect performance when present sub-clinically, as this work clearly illustrates.”
The farm where the study was carried out ran a closed herd with relatively good biosecurity and high health status, with routine bulk tank and youngstock blood testing being carried out. Suspicions of disease entering the herd were raised in May 2010 when three cows aborted, prompting the investigation and creating the opportunity to conduct the study.
“The herd was not being vaccinated against IBR as it was known from regular diagnostic testing to be clear of this particular disease, as well as the other major infectious diseases,” continues Mr Statham. “Following the abortions, investigations revealed the presence of IBR. The route of entry of the virus to the herd remains unknown but may have been through contact with neighbouring cattle, or could have been brought onto the farm on clothing, machinery or even in bull semen. It spread to affect 70% of cows in the herd.
“By comparing performance of seropositive and seronegative cows throughout the herd, over a long period, we have established the impact on milk yield specifically, something that can easily be translated into a financial cost.
“At current milk prices, the cost of sub-clinical IBR was shown to be costing as much as £200 per cow per year, approximately twice the median cost of all veterinary and medicine inputs per cow per year.
“These findings underline the importance of monitoring subclinical infectious disease in dairy herds as part of herd health and production management. The financial cost of disease should also motivate dairy farmers to implement robust biosecurity and biocontainment plans on their farms and give due consideration to marker vaccination programmes for their cattle.”
Note to editors:
The paper ‘Reduction in daily milk yield associated with subclinical bovine herpes virus 1 infection’ (J.M.E Statham, L.V. Randall, S.C. Archer) was published in Veterinary Record (2015) 177, 339.
About MSD Animal Health
Today's MSD is a global healthcare leader working to help the world be well. MSD Animal Health, known as Merck Animal Health in the United States and Canada, is the global animal health business unit of MSD. Through its commitment to theScience of Healthier Animals™, MSD Animal Health offers veterinarians, farmers, pet owners and governments one of the widest range of veterinary pharmaceuticals, vaccines and health management solutions and services. MSD Animal Health is dedicated to preserving and improving the health, well-being and performance of animals. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. MSD Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit www.msd-animal-health.com or connect with us on LinkedIn.
Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA
This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in
the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2014 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).